NCT00514267

An Open-Label Study of YM155 + Docetaxel in Subjects With Advanced Hormone Refractory Prostate Cancer and Other Solid Tumors

A Phase I/II Multicenter, Open-Label Study of YM155 Plus Docetaxel in Subjects With Advanced Hormone Refractory Prostate Cancer and Other Solid Tumors

• Status: Completed
• Phase: Phase 1 / Phase 2
• Study type: Interventional
• Enrollment: 32 (actual)
• Sponsor: Astellas Pharma Inc · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

To determine the feasibility and safety of administering YM155 in combination with docetaxel

Detailed description

This clinical trial is designed to include two parts: Part 1: Assessment of feasibility and safety of administering YM155 in combination with docetaxel and prednisone in subjects with hormone refractory prostate cancer (HRPC) \[ ENROLLMENT COMPLETED \] Part 2: Assessment of feasibility and safety of administering YM155 in combination with docetaxel in subjects with solid tumors (except HRPC). This registration has been updated to reflect the design requirements of PART 2.

Conditions

• Prostate Cancer
• Tumors

Interventions

Type	Name	Description
DRUG	YM 155	IV
DRUG	Docetaxel	IV
DRUG	Prednisone	Oral

Timeline

• Start date: 2007-05-01
• Primary completion: 2010-03-01
• Completion: 2010-03-01
• First posted: 2007-08-09
• Last updated: 2015-08-13

Locations

1 site across 1 country: United States